USA / 5 Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support changes to the system that can lower…
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
Certara’s Ulrich Neumann examines some of the major US market access trends of the past few years, including…
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
Gary Zieziula, president & region head North America for Kyowa Kirin, a specialty care-focused Japan-based global pharma company, highlights the tremendous growth the affiliate has seen over the past three years on track to become a USD 500 million+ organization within the next year; the exciting products and assets that will continue to drive growth for Kyowa Kirin in North…
In 2020, the US FDA’s Center for Drug Evaluation & Research (CDER) approved 53 novel drugs, up from 48 in…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced,…
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar have on US healthcare today and…
Despite the savings and increased patient access biosimilars have brought to health care systems across Europe, the…
David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term…
David H. Crean summarizes the recent 39th annual J.P. Morgan Healthcare Conference 2021 that was held in a virtual…
Following on from our profile on five of the most promising clinical-stage biotech companies developing orphan…
After five years with Takeda heading up the Japan-headquartered pharma company’s US business, following the…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA…
Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why…
From almost being de-listed by the NASDAQ stock index in 2018 due to poor financial performance, US vaccine firm…
In the third of a series of articles chronicling Biogen/Eisai’s Alzheimer’s Disease (AD) treatment…
Photodynamic therapy (PDT) firm Photocure is probably Norway’s most significant recent international healthcare…
After 15 years as director at the Friedrich Miescher Institute for Biomedical Research (FMI) (2004-2019) and even…
US healthcare is often seen as a fragmented system of contrasts. The country has the highest healthcare…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic…